Cabaletta Bio Inc (CABA) 20 Days SMA touches 20.74%: The odds favor the bear

Cabaletta Bio Inc (NASDAQ: CABA) kicked off on Monday, up 8.12% from the previous trading day, before settling in for the closing price of $3.82. Over the past 52 weeks, CABA has traded in a range of $1.76-$26.35.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

While this was happening, its average annual earnings per share was recorded -40.16%. With a float of $41.36 million, this company’s outstanding shares have now reached $48.85 million.

Considering the fact that the conglomerate employs 103 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 71.2%, operating margin of -2855.41%, and the pretax margin is -2597.61%.

Cabaletta Bio Inc (CABA) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cabaletta Bio Inc is 15.37%, while institutional ownership is 89.53%. The most recent insider transaction that took place on Jan 19 ’24, was worth 215,439. In this transaction an insider of this company sold 11,000 shares at a rate of $19.59, taking the stock ownership to the 20,000 shares. Before that another transaction happened on Dec 19 ’23, when Company’s insider sold 11,000 for $21.89, making the entire transaction worth $240,789. This insider now owns 20,000 shares in total.

Cabaletta Bio Inc (CABA) Earnings and Forecasts

In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.46 earnings per share (EPS), lower than consensus estimate (set at -0.39) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -40.16% per share during the next fiscal year.

Cabaletta Bio Inc (NASDAQ: CABA) Trading Performance Indicators

Take a look at Cabaletta Bio Inc’s (CABA) current performance indicators. Last quarter, stock had a quick ratio of 8.11.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.16, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -2.62 in one year’s time.

Technical Analysis of Cabaletta Bio Inc (CABA)

Compared to the last year’s volume of 1.35 million, its volume of 10.53 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 65.56%. Additionally, its Average True Range was 0.60.

During the past 100 days, Cabaletta Bio Inc’s (CABA) raw stochastic average was set at 33.81%, which indicates a significant decrease from 64.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 224.20% in the past 14 days, which was higher than the 131.86% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $3.90, while its 200-day Moving Average is $9.55. Nevertheless, the first resistance level for the watch stands at $5.09 in the near term. At $6.05, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.64. If the price goes on to break the first support level at $3.54, it is likely to go to the next support level at $2.95. Should the price break the second support level, the third support level stands at $1.99.

Cabaletta Bio Inc (NASDAQ: CABA) Key Stats

The company with the Market Capitalisation of 256.18 million has total of 48,877K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -67,680 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -30,630 K.